Denmark's Zealand Pharma Surges as Liver Disease Treatment Shows Promising Results

Zealand Pharma's shares surged following positive results from a trial of its liver disease treatment. The survodutide drug demonstrated efficacy in treating liver inflammation caused by excess fat cells, with 83% of adults showing positive results. The drug has received fast-track designation from the FDA and is undergoing Phase-3 trials for obesity. Analysts are optimistic about its potential in the obesity market, with several firms competing in the sector. Boehringer Ingelheim is overseeing the drug's clinical development.